ALB and chronic kidney disease: The broader health care impact was estimated through costs and net monetary benefit.<h4>Analytical approach</h4>A validated Markov state microsimulation model (CKD progression model) using 18 health states, defined by eGFR and urinary albumin-creatinine ratio thresholds defined by Kidney Disease: Improving Global Outcomes (KDIGO).<h4>Results</h4>Based on prevalence and incidence of CKD, the model predicts a 30% increase in the population of individuals with CKD stages G3-G5 from 251,946 in 2026 to 328,414 in 2035 with the current practice.